Literature DB >> 1615547

Emergency reversal of anticoagulation after intracerebral hemorrhage.

K Fredriksson1, B Norrving, L G Strömblad.   

Abstract

BACKGROUND AND
PURPOSE: Although intracerebral hemorrhage is one of the most serious complications during oral anticoagulant therapy, there are no guidelines on emergency treatment with respect to reversal of anticoagulation effect in these patients.
METHODS: We retrospectively compared laboratory data and clinical features in 17 cases of anticoagulant-related intracerebral hemorrhage treated with prothrombin complex concentrate (n = 10) or fresh-frozen plasma (n = 7).
RESULTS: In the group of patients treated with prothrombin complex concentrate, the mean prothrombin time decreased from 2.83 to 1.22 International Normalized Ratio within 4.8 hours, compared with a decrease from 2.97 to 1.74 within 7.3 hours in those given fresh-frozen plasma (i.e., four to five times more rapidly after treatment with prothrombin complex concentrate) (p less than 0.001). Symptoms and signs of intracerebral hemorrhage, measured on an eight-graded Reaction Level Scale, progressed on average 0.2 grades in patients given prothrombin complex concentrate compared with 1.9 grades in those given fresh-frozen plasma (p less than 0.05). In patients with prothrombin values above 1.46, clinical progression within 12 hours occurred in five of six cases.
CONCLUSIONS: Treatment with prothrombin complex concentrate reverses anticoagulation more rapidly than fresh-frozen plasma, which might be of importance for the prevention of further bleeding.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1615547     DOI: 10.1161/01.str.23.7.972

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  63 in total

Review 1.  Practical issues with vitamin K antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure.

Authors:  Andrea Lee; Mark Crowther
Journal:  J Thromb Thrombolysis       Date:  2011-04       Impact factor: 2.300

Review 2.  Prothrombin complex concentrates: an update.

Authors:  Massimo Franchini; Giuseppe Lippi
Journal:  Blood Transfus       Date:  2010-07       Impact factor: 3.443

3.  [Recommendations of the European Stroke Initiative for the diagnosis and treatment of spontaneous intracerebral haemorrhage].

Authors:  S Külkens; P Ringleb; J Diedler; W Hacke; T Steiner
Journal:  Nervenarzt       Date:  2006-08       Impact factor: 1.214

Review 4.  Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Anne Holbrook; Sam Schulman; Daniel M Witt; Per Olav Vandvik; Jason Fish; Michael J Kovacs; Peter J Svensson; David L Veenstra; Mark Crowther; Gordon H Guyatt
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 5.  Novel oral anticoagulants: pharmacology, coagulation measures, and considerations for reversal.

Authors:  Larry R Jackson; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2014-04       Impact factor: 2.300

6.  Prothrombin complex concentrates utility for warfarin-associated hemorrhage.

Authors:  Secgin Soyuncu; Savas Aslan; Halil Mutlu; Firat Bektas
Journal:  Int J Clin Exp Med       Date:  2015-02-15

7.  Intracerebral hemorrhage: clinical overview and pathophysiologic concepts.

Authors:  Fred Rincon; Stephan A Mayer
Journal:  Transl Stroke Res       Date:  2012-04-21       Impact factor: 6.829

Review 8.  Prothrombin complex concentrates for oral anticoagulant therapy-related intracranial hemorrhage: a review of the literature.

Authors:  Eric M Bershad; Jose I Suarez
Journal:  Neurocrit Care       Date:  2010-06       Impact factor: 3.210

Review 9.  Why develop antidotes and reversal agents for non-vitamin K oral anticoagulants?

Authors:  Jeffrey B Washam; Jonathan P Piccini
Journal:  J Thromb Thrombolysis       Date:  2016-02       Impact factor: 2.300

Review 10.  [Intracerebral hemorrhage related to anticoagulant therapy].

Authors:  H B Huttner; E Jüttler; A Hug; M Köhrmann; P D Schellinger; T Steiner
Journal:  Nervenarzt       Date:  2006-06       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.